CGK733 enhances multinucleated cell formation and cytotoxicity induced by taxol in Chk1-deficient HBV-positive hepatocellular carcinoma cells

Biochemical and Biophysical Research Communications

Volumn 422, Issue 1, 2012, Pages 103-108

  Wang, Huan ^a   Zuo, Bin ^a   Wang, Haibin ^a   Ren, Laifeng ^a   Yang, Peng ^a   Zeng, Ming ^a   Duan, Dan ^a   Liu, Cong ^a   Li, Mingyuan ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

CGK733; Hepatitis B virus (HBV); Hepatocellular carcinoma (HCC); Taxol

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN; CGK 733; CHECKPOINT KINASE 1; CISPLATIN; DOXORUBICIN; PACLITAXEL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELASTRACEAE; CELL MATURATION; CELL STRAIN HEPG2; CHROMOSOMAL INSTABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOSIS; MULTINUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENEACETAMIDES; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GIANT CELLS; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; THIOUREA; TUMOR SUPPRESSOR PROTEINS;

HEPATITIS B VIRUS;

EID: 84861462158     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.115     Document Type: Article

References (31)

1. Severi T., Van Malenstein H., Verslype C., et al. Tumor initiation and progression in hepatocellular carcinoma risk factors, classification, therapeutic targets. Acta Pharmacologica Sinica. 2010, 31(11):1409-1420.
2. Zhou Z.R., Li F. Medical microbiology [M]. People's Medical Publishing House 2005, 291.
3. Wei W., Chua MS., Grepper S., et al. Small molecule antagonists of Tcf4/ beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int. J. Cancer 2010, 126(10):2426-2436.
4. Samadi N., Bekele R.T., Goping I.S., et al. Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest. PLoS One 2011, 6(5):e20608.
5. Gao G., Chu H., Zhao L., et al. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3weeks first-line treatment of advanced non-small-cell lung cancer. Lung Cancer 2012.
6. Liu Y.L., Zhang Y.L., Fu J.H., et al. Chemotherapeutic effects of different paclitaxel plus poldine combination methods for treatment of ovarian carcinoma. Asian Pac. J. Cancer Prev. 2011, 12(7):1713-1716.
7. Mauri D., Kamposiora K., Tsali L., et al. Overall survival benefit for weekly vs. three - weekly taxanes regimens in advanced breast cancer. A meta-analysis. Cancer Treat. Rev. 2010, 36(1):69-74.
8. Chun E., Lee K.Y. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 2004, 315(3):771-779.
9. Kuo T.C., Lu H.P., Chao C.C. The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochem. Pharmacol. 2011, 82(2):184-194.
10. S, Chae, Y.B. Kim, J.S. Lee et al., Resistance to paclitaxel in hepatoma cells is related to static JNK activation prohibition into entry of mitosis, Am. J. Physiol. Liver Physiol. (2012) Feb 9. [Epub ahead of print].
11. Jazayeri A., Falck J., Lukas C., et al. ATM - and cell cycle dependent regulation of ATR in response to DNA double-strand breaks. Nature Cell Biol. 2006, 8(1):37-45.
12. Sarkaria J.N., Eshleman J.S. ATM as a target for novel radio sensitizers. Semin. Radiat. Oncol. 2001, 11(4):316-327.
13. Crescenzi E., Palumbo G., de Boer J., et al. Ataxia telangiectasia mutated and p21 (CIP1) modulate cell survival of drug-induced senescent tumor cells: Implications for chemotherapy. Clin. Cancer Res. 2008, 14(6):1877-1887.
14. Wang T., Zhao R., Wu Y., et al. Hepatitis B virus induces G1 phase arrest by regulating cell cycle genes in HepG2. 2. 15 cells. Virol. J. 2011, 8:231.
15. Bhattacharya S., Ray R.M., Johnson L.R. Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells. Cell Signal. 2009, 21(4):509-522.
16. Zachos G., Black E.J., Walker M., et al. Chk1 is required for spindle checkpoint function. Develop. Cell 2007, 12(2):247-260.
17. Durkin S.G., Arlt M.F., Howlett N.G., et al. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene 2006, 25(32):4381-4388.
18. Bekier M.E., Fischbach R., Lee J., et al. Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit. Mol. Cancer Ther. 2009, 8(6):1646-1654.
19. Kang J., Hu H.T. Kinase signaling in the spindle checkpoint. J. Biol. Chem. 2009, 284(23):15359-15363.
20. Schmidt M., Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist. Updat. 2007, 10(4-5):162-181.
21. Galluzzi L., Vitale I., Abrams J.M., et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ. 2012, 19:107-120.
22. Vitale I., Galluzzi L., Castedo M., et al. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat. Rev. Mol. Cell Biol. 2011, 12(6):385-392.
23. Yue Q.X., Liu X., Guo D.A. Microtubule-binding natural products for cancer therapy. Planta Medica 2010, 76(11):1037-1043.
24. Wilsker D., Petermann E., Helleday T., et al. Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc. Natl. Acad. Sci. 2008, 105(52):9236-9241.
25. Rodrguez-Antona C. Pharmacogenomics of paclitaxel. Pharmacogenomics 2010, 11(5):621-623.
26. Zajac M., Gomez G., Benitez J., et al. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer. BMC Med. Genom. 2010, 3(44).
27. Shao W.L., Growney J.D., Feng Y., et al. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance. Int. J. Cancer 2010, 127(9):2199-2208.
28. Shi Y.K., Li Z.H., Han X.Q., et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. Cancer Chemother. Pharmacol. 2010, 66:1131-1140.
29. Won J.J., Kim M., Kim N., et al. Small molecule-based reversible reprogramming of cellular lifespan. Nature Chem. Biol. 2006, 2(7):369-374.
30. Michalakis J., Georgatos S.D., Romanos J., et al. Micromolar taxol, with or without hyperthermia, induces mitotic catastrophe cell necrosis in Hela cells. Cancer Chemother. Pharmacol. 2005, 56:615-622.
31. Wenz F., Greiner S., Germa F., et al. Radiochemotherapy with paclitaxel: synchronization effects the role of p53. Strahlenther Onkol. 1999, 175(Suppl. 3):2-6.